Vincent Rajkumar: VRd transplant and Len maintenance for frontline therapy in newly diagnosed myeloma

Vincent Rajkumar, Professor of Medicine at the Mayo Clinic, shared on X:

“While we recommend quadruplets for newly diagnosed myeloma, that is provided these treatments are available and affordable.

In most of the world they are NOT.

VRd transplant (if eligible) and Len maintenance is just fine for frontline therapy for most patients.

So if you are not able to give quads or Dara maintenance don’t feel bad, and certainly patients should not think they are getting inferior care.

OS is extremely good and similar at 5 years with VRd, transplant, Len maintenance.

Most of the marked improvement in survival in myeloma that has occurred in the last 20 years is due to addition of Lenalidomide and Bortezomib to the older treatments.”

More posts featuring Vincent Rajkumar on oncodaily.com

Vincent Rajkumar is a Professor of Medicine at the Mayo Clinic in Rochester, Minnesota, and Chair for the Mayo Clinic Myeloma, Amyloidosis, and Dysproteinemia Group.  He also chairs the Board of directors of  The International Myeloma Foundation and the Eastern Cooperative Oncology Group (ECOG) Myeloma Committee.

His extensive contributions include over 230 peer-reviewed publications, predominantly focusing on multiple myeloma and related plasma cell disorders. Furthermore, Dr. Rajkumar is a Section Editor for multiple myeloma and related disorders for Leukemia and an Associate Editor for the Mayo Clinic Proceedings.